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The ethical imperative to treat NCDs during research in Africa
As the rising prevalence and life-threatening 
consequences of non-communicable diseases (NCDs) 
in Africa have become more obvious,1 so too has the 
fact that many African health systems are ill-equipped 
to meet the health-care needs of local communities 
affected by NCDs.2 Meanwhile, the quantity of clinical 
research done in Africa continues to increase,3 and 
carries with it unique ethical questions, especially 
relating to the amount of NCD medical care that ought 
to be provided for participants involved in this research. 
Many African research participants, whether enrolled 
in studies that investigate NCDs or other diseases, will 
inevitably have NCDs, but have little to no access to 
NCD health care in their communities. NCDs present a 
unique challenge because, contrary to acute infectious 
processes, the treatment of NCDs is not usually urgent 
and a lack of care will not lead to immediate morbidity 
or mortality. As such, do researchers in Africa have 
a responsibility to provide ancillary NCD services to 
research participants? In light of the third UN High-
Level Meeting on NCDs, our aim is to provoke a dialogue 
regarding ancillary NCD services in the context of 
research in Africa. We believe that this dialogue can 
be guided by several lessons learned during the HIV 
epidemic and by a moral responsibility to provide 
ancillary care as articulated by Richardson.4
First, researchers in Africa should strive for the 
“highest achievable standard” of ancillary care for 
NCDs diagnosed during the course of medical research.5 
Setting standards that are too high for ancillary 
NCD services will make the conduct of research too 
burdensome.6,7 By contrast, accepting health inequity 
as an unchangeable reality misses the opportunity for 
research to combat these inequities.5,8–11 Determining 
this “highest achievable standard” will require an in-
depth understanding of the social, economic, and 
political contexts of the settings for each study.5
Second, the “highest achievable standard” should 
be continuously reassessed and increased on the basis 
of improvements in the local health-care system and 
new scientific knowledge. During the initial decades 
(1995–2010) of HIV research in Africa, for example, the 
local capacity to provide antiretroviral treatment (ART) 
increased dramatically.12 Therefore, the standard for 
ancillary HIV care in Africa also increased to the point 
of ART being provided for participants in HIV trials.8,12,13 
Members of one HIV trial network noted that, “One 
research organization cannot reverse global inequities 
in HIV[-1] care but researchers…have an obligation to try 
to narrow the equity gap.”12
Third, study-specific guidelines regarding ancillary 
care for NCDs should be guided by the “four Ps”: positive 
duty, planning, partnership, and practical provisions.10 
Researchers have a duty to assist study participants 
diagnosed with NCDs: careful planning is needed to 
anticipate the NCD burden in the study population; NCD 
care plans should be developed in partnership with the 
local community to prevent displacing or disrupting 
the local health-care system; and investigators should 
clearly state the planned NCD provisions.
Fourth, study-specific ancillary care plans for NCDs 
should be guided by the nature of the relationships 
between the study participants, the investigators, and 
the community.4 One working group suggested a series 
of questions helpful in evaluating ancillary care needs, 
including “how severe or acute are the likely ancillary 
care needs”, is the identification of NCDs “integral 
or incidental to carrying out study procedures”, and 
“how extensive are the proposed interactions between 
researchers and study participants”.10 The final plan for 
ancillary NCD services should be the result of a moral 
negotiation between community members and the 
research study team.11
Finally, in our own research14,15 in east Africa, we have 
learned that high-quality ancillary services for common 
NCDs can be provided through the local health system 
at a reasonable cost. For example, in a cohort study of 
adults with HIV funded by the US National Institutes of 
Health, we raised modest private funds to provide free 
treatment for hypertension and diabetes. The HIV clinic 
used these funds to purchase high-quality generic drugs 
from a local pharmacy. Furthermore, we helped the 
HIV clinic’s case manager to develop a system to track 
blood pressure, blood glucose control, and prescription 
refills. We also worked with HIV staff to incorporate 
hypertension and diabetes screening into routine clinic 
services and to develop locally relevant NCD health 
education.
In conclusion, the medical research community in 
Africa has the opportunity and the moral responsibility 
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to help combat the NCD epidemic in Africa through 
the provision of appropriate ancillary services for NCDs. 
Further dialogue is needed to help researchers and 
sponsors articulate the extent of this moral imperative.
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